Alqahtani, et al15a | Dhoble, et al4a,b | Thakkar, et al17a,b | Greason, et al2 | Schill, et al16 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
TAVR | SAVR | TAVR | SAVR | TAVR | SAVR | TAVR | SAVR | TAVR | SAVR | |
Characteristic | n=174 | n=1,592 | n=126 | n=157 | n=36 | n=93 | n=6 | n=12 | n=17 | n=18 |
Mean age, years | 72 | 64 | 71.7 | 65.3 | 73.4 | 66 | 76 | 68 | 73.8 | 55.1 |
Male | 108 (62.1) | 1,041 (65.4) | (58.7) | (65.6) | (77.8) | (67.7) | 5 (83) | 10 (83) | 12 (70.6) | 12 (66.7) |
Mean MELD score | NA | NA | NA | NA | NA | NA | 9 | 10 | 10.7 | 11.8 |
Chronic kidney disease | 77 (44.3) | 369 (23.2) | NA | NA | NA | NA | NA | NA | 1 (5.9) | 4 (22.2) |
Hypertension | 124 (71.3) | 785 (49.3) | NA | NA | (69.4) | (66.7) | NA | NA | 15 (88.2) | 11 (61.1) |
Diabetes | 88 (50.6) | 447 (28.1) | (60.3) | (47.1) | (58.3) | (47.3) | 3 (50) | 3 (25) | 11 (64.7) | 4 (22.2) |
Congestive heart failure | 21 (12.1) | 134 (8.4) | (70.6) | (49.0) | 0 | (4.3) | 6 (100)c | 6 (50)c | 15 (88.2) | 10 (55.6) |
Peripheral artery disease | 48 (27.6) | 271 (17.0) | (21.4) | (10.2) | (19.4) | (14.0) | 4 (66.7) | 2 (16.7) | 7 (41.2) | 1 (5.6) |
Atrial fibrillation or flutter | 63 (36.2) | 659 (41.4) | NA | NA | NA | NA | NA | NA | NA | NA |
Chronic lung disease | 55 (31.6) | 379 (23.8) | NA | NA | (27.8) | (32.3) | 3 (50) | 3 (25) | 8 (47.1) | 7 (38.9) |
↵aPropensity score–matched cohort study.
↵bPatient numbers (n) not provided in the article for the characteristics.
↵cNew York Heart Association class III-IV only.
Note: Data are presented as n (%) or as (%) unless otherwise indicated.
MELD, Model for End-Stage Liver Disease; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.